Delcath Systems Stock News

Delcath Systems, Inc. (OTCMKTS:DCTH) shot up 16.7% during trading on Friday . The company traded as high as $10.95 and last traded at $10.78, 104,100 shares traded hands during trading. An increase of

Appoints John Purpura as interim Chief Executive Officer. NEW YORK, May 26, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (DCTH), an interventional oncology company focused on liver-directed treat

SINGAPORE, May 24, 2020 (PR Newswire Europe via COMTEX) -- Singapore medtech company HistoIndex [https://www.histoindex.com/]'s AI-based stain-free digital...

Dover, Delaware--(Newsfile Corp. - May 19, 2020) - Encode Ideas, L.P. Initiates Research on Delcath Systems, Inc (NASDAQ: DCTH). The full research publication is available here and available on our we

Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announces financial results for the quarter ended March 3

Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced the closing of its previously announced u

Delcath Systems, Inc. (OTCQB:DCTH  NASDAQ:DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced the pricing of a $22

Delcath Systems appoints Elizabeth Czerepak to board of directors DCTH

Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announced that Elizabeth Czerepak, a financial executive and board m

Delcath Systems completes enrollment in FOCUS registration trial DCTH

Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced it has completed patient enrollment in it

Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announced that the Company’s Board of Directors has authorized a 1-

NEW YORK, Dec. 03, 2019 -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today.

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Melphalan/HDS has not been approved by the U.S. Food & Drug Administratio

Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the Company’s Board of Directors has authorized a re